Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus
V. E. Syutkin,
V. R. Gorodetskiy,
A. A. Salienko,
N. A. Probatova,
N. A. Kupryshina,
M. S. Novruzbekov https://doi.org/10.23873/2074-0506-2021-13-3-272-279
Abstract
Introduction. One of the serious complications after transplantation of solid organs and bone marrow is the development of post-transplant lymphoproliferative diseases.
Clinical case. To evaluate the course of post-transplant lymphoproliferative diseases in the long-term in a liver transplant recipient after conversion of immunosuppressive therapy from tacrolimus to everolimus. We analyze a case of generalized primary plasmacytoma of lymph nodes with bone marrow involvement in a patient after liver transplantation.
Results. After conversion of immunosuppression we observed a rapid positive trend: decreasing size of lymph nodes and regression of the level of paraprotein down to its complete disappearance. There were neither adverse events associated with everolimus for four years, nor signs of immunosuppression insufficiency.
Conclusion. This Case Report is the first description of a long-term remission of nodal plasmacytoma that developed in a liver transplant recipient after complete withdrawal of calcineurin inhibitors and administration of everolimus. We suggest that the regression of post-transplant lymphoproliferative diseases after replacing calcineurin inhibitors with everolimus is associated not only with the minimization of calcineurin inhibitors exposure, but also with the antitumor effect of the everolimus itself, which prompts us to discuss the possibilities of expanding its clinical application.
About the Authors
V. E. Syutkin
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Vladimir E. Syutkin, Dr. Sci. (Med.), Leading Research Associate, Department for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
V. R. Gorodetskiy
Research Institute of Rheumatology n.a. V.A. Nasonova
Russian Federation
Russian Federation
Vadim R. Gorodetskiy, Cand. Sci. (Med.), Leading Researcher, Laboratory of Intensive Therapy Methods
34A Kashirskoe Dr., Moscow 115522
A. A. Salienko
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Anastasiya A. Salienko, Surgeon of the Operating Theatre for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
N. A. Probatova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Nataliya A. Probatova, Dr. Sci. (Med.), Consultant of the Department for Morphological and Molecular-
Genetic Diagnosis of Tumors
23 Kashirskoe Dr., Moscow 115478
N. A. Kupryshina
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Natalya A. Kupryshina, Cand. Sci. (Med.), Senior Researcher, Laboratory of Hematopoiesis Immunology at Clinical and Laboratory Departmen
23 Kashirskoe Dr., Moscow 115478
M. S. Novruzbekov
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Murad S. Novruzbekov, Dr. Sci. (Med.), Head of the Scientific Department for Liver Transplantation
3 Bolshaya Sukharevskaya Sq., Moscow 129090
References
1. Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J. 1968;4(5633):746–748. PMID: 4881420 https://doi.org/10.1136/bmj.4.5633.746
2. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583–587. PMID: 6142304 https://doi.org/10.1016/s0140-6736(84)90994-2
3. Swerdlow S. Post-transplant lymphoproliferative disorders. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4 th ed. Lyon: International Agency for Research on Cancer; 2017. p. 453–462.
4. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155–167. PMID: 15979320 https://doi.org/10.1016/j.critrevonc.2005.03.015
5. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–726. PMID: 15009059 https://doi.org/10.1111/j.1365-2141.2004.04834.x
6. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765. PMID: 22654647 https://doi.org/10.1100/2012/895765
7. Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell posttransplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011;96(7):1067–1071. PMID: 21719885 https://doi.org/10.3324/haematol.2010.039214
8. Richendollar BG, Hsi ED, Cook JR. Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features. Am J Clin Pathol. 2009;132(4):581– 588. PMID: 19762536 https://doi.org/10.1309/AJCPX70TIHETNBRL
9. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–183. PMID: 23737188 https://doi.org/10.1007/s11899-013-0162-5
10. El-Salem M, Raghunath PN, Marzec M, Wlodarski P, Tsai D, Hsi E, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest. 2007;87(1):29–39. PMID: 17075574 https://doi.org/10.1038/labinvest.3700494
11. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63(15):4472–4480. PMID: 12907620
12. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA. 2000;97(8): 4285–4290. PMID: 10759564 https://doi.org/10.1073/pnas.080068597
13. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75(10):1710–1717. PMID: 12777861 https://doi.org/10.1097/01.TP.0000063934.89714.19
14. Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus- induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47(5):e67–72. PMID: 16632009 https://doi.org/10.1053/j.ajkd.2006.01.029
15. Boratynska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int. 2008;21(6):605– 608. PMID: 18282244 https://doi.org/10.1111/j.1432-2277.2008.00655.x
16. Pascual J. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(Suppl 1): i27–35. PMID: 17456616 https://doi.org/10.1093/ndt/gfm088
17. Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient. Transpl Infect Dis. 2019;21(4):e13116. PMID: 31102475 https://doi.org/10.1111/tid.13116
18. Li J, Liu Z, Li Y, Jing Q, Wang H, Liu H, et al. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway. J Investig Med. 2019;67(1):39–47. PMID: 29997148 https://doi.org/10.1136/jim-2018-000780
19. Günther A, Baumann P, Burger R, Kellner C, Klapper W, Schmidmaier R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100(4):541–547. PMID: 25682600 https://doi.org/10.3324/haematol.2014.116269
20. Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23(2):97–125. PMID: 23165654 https://doi.org/10.1002/rmv.1733
21. Pascual J, Royuela A, Fernández AM, Herrero I, Delgado JF, Solé A, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819–831. PMID: 27600985 https://doi.org/10.1111/tid.12601
Review
For citations:
Syutkin V.E., Gorodetskiy V.R., Salienko A.A., Probatova N.A., Kupryshina N.A., Novruzbekov M.S. Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus. Transplantologiya. The Russian Journal of Transplantation. 2021;13(3):272-279. https://doi.org/10.23873/2074-0506-2021-13-3-272-279
Views:
511
Email this article 